Intravenous Infusion

AstraZeneca · FDA-approved active Small molecule

Intravenous Infusion is a Small molecule drug developed by AstraZeneca. It is currently FDA-approved. Also known as: levodopa, Medicine, Matching Placebo, Paracetamol.

Unable to determine specific mechanism without a named drug product.

At a glance

Generic name	Intravenous Infusion
Also known as	levodopa, Medicine, Matching Placebo, Paracetamol, PCA
Sponsor	AstraZeneca
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

Intravenous infusion is a route of administration rather than a specific drug. Without a brand name, generic name, or molecular target, the mechanism cannot be characterized. AstraZeneca manufactures multiple IV infusion products across different therapeutic areas.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (PHASE1)
• Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
• TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
• A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) (PHASE1, PHASE2)
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
• AAV8-hCocH for Cocaine Use Disorder (PHASE1)
• DDAVP for Pituitary Adenoma (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Intravenous Infusion CI brief — competitive landscape report
• Intravenous Infusion updates RSS · CI watch RSS
• AstraZeneca portfolio CI

Frequently asked questions about Intravenous Infusion

What is Intravenous Infusion?

Intravenous Infusion is a Small molecule drug developed by AstraZeneca.

How does Intravenous Infusion work?

Unable to determine specific mechanism without a named drug product.

Who makes Intravenous Infusion?

Intravenous Infusion is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Intravenous Infusion also known as anything else?

Intravenous Infusion is also known as levodopa, Medicine, Matching Placebo, Paracetamol, PCA.

What development phase is Intravenous Infusion in?

Intravenous Infusion is FDA-approved (marketed).

Related

• Manufacturer: AstraZeneca — full pipeline
• Also known as: levodopa, Medicine, Matching Placebo, Paracetamol, PCA